跳至主要内容
临床试验/NCT02583438
NCT02583438Unknown4 期

Beijing Chao-yang Hospital, Capital Medical University

Beijing Chao Yang Hospital0 个研究点目标入组 100 人开始时间: 2015年10月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
发起方
入组人数
100
主要终点
gut microbiota

研究概览

简要总结

The intestinal microflora imbalance has been associated with obesity and type 2 diabetes. The researchers' study aimed to investigate the effect of saxagliptin on gut microbiota in patients with newly diagnosed type 2 diabetes.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
20 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Females or males, and aged 20 to 65 years.
  • Newly diagnosed type 2 diabetes
  • HbA1C ≥7% and HbA1C <9%

排除标准

  • Hepatic insufficiency (ALT or AST> 1.5*ULN)
  • Renal insufficiency [Creatinine clearance rate (Ccr)]<60ml/min estimated from MDRD equation)
  • Coronary artery disease
  • Thyroid disease
  • Infectious disease
  • Systemic inflammatory disease
  • Subjects who were taking agents known to influence gut microbiota
  • Pregnant or lactating woman
  • Other conditions at investigator's discretion

研究组 & 干预措施

Lifestyle intervention

Experimental

干预措施: Saxagliptin (Bristol-Myers Squibb Company) (Drug)

结局指标

主要结局

gut microbiota

时间窗: Change from Baseline Bacteroidetes abundances and composition of gut microbiota at 6 months

次要结局

  • The improvement of intestinal microflora imbalance(Bacteroidetes abundances and composition of gut microbiota (baseline, 4 weeks, 8 weeks and 12 weeks))
  • The change of inflammatory markers(The change of inflammatory markers (baseline, 12 weeks))

研究者

发起方
Beijing Chao Yang Hospital
申办方类型
Other
责任方
Principal Investigator
主要研究者

Guang Wang

Department of Endocrinology

Beijing Chao Yang Hospital

相似试验